Senate Finance Committee Seeks Review Of Manufacturer Investigations By DOJ, HHS
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Grassley requests briefings on the “scope and subject matter of all pending drug company investigations.” He is concerned that settlements like the Pfizer Neurontin deal are viewed as a cost of doing business.
You may also be interested in...
“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
Pfizer Will Monitor Off-Label Drug Use And Report To IG Under Neurontin Settlement
Corporate integrity agreement will be carefully studied in pharmaceutical industry given uncertainties surrounding off-label promotion rules. Pfizer agrees to establish clear policies and keep close tabs on off-label use – but the agreement does not define prohibited or permitted activities.